AMRI to Receive Second Milestone Payment from Licensing Agreement with Bristol-Myers Squibb.
Linked as:
Extract
AMRI to Receive Second Milestone Payment from Licensing Agreement with Bristol-Myers Squibb.
ALBANY, N.Y. -- AMRI (NASDAQ: AMRI) announced today it will receive a $4 million milestone payment from Bristol-Myers Squibb Company (NYSE: BMY) as a result of Bristol-Myers Squibb's submission of a Clinical Trial Application (CTA) to the Health Product...
See the full content of this document
Sponsored links
